Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The transplantation of mesenchymal stem cells (MSCs) for treating neurodegenerative disorders has received growing attention recently because these cells are readily available, easily expanded in culture, and when transplanted, survive for relatively long periods of time. Given that such transplants have been shown to be safe in a variety of applications, in addition to recent findings that MSCs have useful immunomodulatory and chemotactic properties, the use of these cells as vehicles for delivering or producing beneficial proteins for therapeutic purposes has been the focus of several labs. In our lab, the use of genetic modified MSCs to release neurotrophic factors for the treatment of neurodegenerative diseases is of particular interest. Specifically, glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and brain derived neurotrophic factor (BDNF) have been recognized as therapeutic trophic factors for Parkinson’s, Alzheimer’s and Huntington’s diseases, respectively. The aim of this literature review is to provide insights into: (1) the inherent properties of MSCs as a platform for neurotrophic factor delivery; (2) the molecular tools available for genetic manipulation of MSCs; (3) the rationale for utilizing various neurotrophic factors for particular neurodegenerative diseases; and (4) the clinical challenges of utilizing genetically modified MSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941 · cited 1×
“6 million people were affected with Alzheimer’s disease (AD) worldwide in 2010 [142] and the prevalence is expected to quadruple by 2050, with 1 in 85 people living with AD [143].”
BackgroundZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 1×
“neocortex, respectively [150].”
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“Additionally, the state of BBB function, through the progression of a disease or injury [49] may impact the therapeutic efficacy of systemic administrated MSCs.”
BackgroundJohnstone, R. M., Adam, M., Hammond, J. R., Orr, L., & Turbide, C. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48095-7 · Cited by 2,931 · cited 1×
“These exosomes were originally considered solely responsible for the removal of aberrant materials [58], but now have”
BackgroundLe Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 1×
“Observations of a reduction of neurons in the basal forebrain cholinergic nuclei (BFChN) and reduced levels of choline acetyltransferase, acetylcholine, and acetylcholinesterase (AChE) in the hippocampus and neocortex led to the development of the cholinergic hypothesis of AD [151].”
BackgroundNeurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944 · cited 1×
“there are many other identified signaling pathways [161].”
BackgroundInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854 · cited 1×
“retrovirus vector as led to insertional mutagenesis, resulting in activation of proto-oncogenes in four of fifteen patients [73].”
BackgroundAlzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
TALENs: A widely applicable technology for targeted genome editing
Joung, J. K., & Sander, J. D. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3486 · Cited by 1,650 · cited 2×
“Zinc finger nuclease (ZFN) [95], transcription activator-like effector nuclease (TALEN) [96], and the CRISPR/Cas system [97] are new tools for genetic modification.”
BackgroundHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 3×
“Clinical success utilizing a lentiviral vector has been observed in the treatment of X-linked adrenoleukodystrophy in the same fashion as X-linked SCID [75], but without any reported complications.”
BackgroundDirect brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · cited 3×
“While direct infusion of NGF has had complications, a clinical trial of eight AD patients utilizing autologous fibroblasts, engineered to express NGF, were transplanted into the nucleus basalis of Meynert which produced NGF expression in grafts, a reduced decline or improvement of Mini-Mental Status Examination scores…”
BackgroundImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 1×
“to its lack of integration, although problems of immunogenicity are still of concern [80].”
BackgroundMolecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848 · cited 1×
“However, there is many other hypotheses, including excitotoxicity, proteolysis, protein misfolding, autophagy, and mitochondrial dysfunctions, have also been implicated in the pathology of HD [190].”
BackgroundStem Cell Paracrine Actions and Tissue Regeneration
Baraniak, P. R., & McDevitt, T. C. (2010) · Regenerative Medicine · doi:10.2217/rme.09.74 · Cited by 843
GDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820 · cited 1×
“The history of both clinical and pre-clinical trials reveal that MSCs provide considerable promise as therapeutic agents [211–213], especially as sources for producing or vectors for delivering neurotrophic factors [214] for the treatment of neurodegenerative diseases (see Table 1).”
BackgroundWirth, T., Parker, N., & Ylä-Herttuala, S. (2013) · Gene · doi:10.1016/j.gene.2013.03.137 · Cited by 607
Rocca, W. A., Petersen, R. C., Knopman, D. S., Hebert, L. E., Evans, D. A., Hall, K. S., Gao, S., Unverzagt, F. W., Langa, K. M., Larson, E. B., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.11.002 · Cited by 498 · cited 1×
“6 million people were affected with Alzheimer’s disease (AD) worldwide in 2010 [142] and the prevalence is expected to quadruple by 2050, with 1 in 85 people living with AD [143].”
BackgroundGenetically Engineered Microvesicles Carrying Suicide mRNA/Protein Inhibit Schwannoma Tumor Growth
Mizrak, A., Bolukbasi, M. F., Ozdener, G. B., Brenner, G. J., Madlener, S., Erkan, E. P., Ströbel, T., Breakefield, X. O., & Saydam, O. (2013) · Molecular Therapy · doi:10.1038/mt.2012.161 · Cited by 337
McBride, J. L., Pitzer, M. R., Boudreau, R. L., Dufour, B., Hobbs, T., Ojeda, S. R., & Davidson, B. L. (2011) · Molecular Therapy · doi:10.1038/mt.2011.219 · Cited by 247 · cited 1×
“Pre-clinical investigations have shown that the use of small-interfering RNAs (siRNAs) which reduce the levels of both mutant and wild-type huntingtin, have, nonetheless, been shown to reduce histological and behavioral deficits in rodents [197–199] and in non-human primates [200,201].”
BackgroundLee, J. K., Jin, H. K., & Bae, J.-S. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2008.11.059 · Cited by 189 · cited 2×
“AD Mouse, Acute amyloid-β aggregate Levels of amyloid-β were reduced following BM-MSC administration [136].”
BackgroundSix-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum
Grondin, R., Kaytor, M. D., Ai, Y., Nelson, P. T., Thakker, D. R., Heisel, J., Weatherspoon, M. R., Blum, J. L., Burright, E. N., Zhang, Z., et al. (2012) · Brain · doi:10.1093/brain/awr333 · Cited by 153
Insertional Gene Activation by Lentiviral and Gammaretroviral Vectors
Bokhoven, M., Stephen, S. L., Knight, S., Gevers, E. F., Robinson, I. C., Takeuchi, Y., & Collins, M. K. (2009) · Journal of Virology · doi:10.1128/jvi.01865-08 · Cited by 138 · cited 2×
“the rate of mutagenesis of a retrovirus and a lentivirus, albeit these were mediated through different mechanisms [77].”
Background
Cited by
Role of Mesenchymal Stem Cells in Bone Regenerative Medicine: What Is the Evidence?
Oryan, A., Kamali, A., Moshiri, A., & Baghaban Eslaminejad, M. (2017) · Cells Tissues Organs · doi:10.1159/000469704 · Cited by 353
Marquez-Curtis, L. A., Janowska-Wieczorek, A., McGann, L. E., & Elliott, J. A. W. (2015) · Cryobiology · doi:10.1016/j.cryobiol.2015.07.003 · Cited by 346
Functional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases
Lo Furno, D., Mannino, G., & Giuffrida, R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26192 · Cited by 177
Alzheimer’s Disease: Advances in Drug Development
Piton, M., Hirtz, C., Desmetz, C., Milhau, J., Lajoix, A. D., Bennys, K., Lehmann, S., & Gabelle, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180145 · Cited by 60
Metadata
- Authors
- Wyse, R., Dunbar, G., & Rossignol, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2014-01-23
- Volume
- 15
- Issue
- 2
- Pages
- 1719-1745
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2052684906
- Cited by
- 80
- References
- 27
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.